# Camrelizumab Combined With CRT for Treatment of Patients With Local Recurrence of Esophageal Cancer

> **NCT04390945** · PHASE2 · UNKNOWN · sponsor: **The First Affiliated Hospital of Henan University of Science and Technology** · enrollment: 62 (estimated)

## Conditions studied

- Esophageal Cancer

## Interventions

- **DRUG:** Camrelizumab

## Key facts

- **NCT ID:** NCT04390945
- **Lead sponsor:** The First Affiliated Hospital of Henan University of Science and Technology
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-12-01
- **Primary completion:** 2023-10
- **Final completion:** 2024-08
- **Target enrollment:** 62 (ESTIMATED)
- **Last updated:** 2022-02-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04390945

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04390945, "Camrelizumab Combined With CRT for Treatment of Patients With Local Recurrence of Esophageal Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04390945. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*